Want to see IMDX full AI Analyst Report?
IMDX Stock Chart & Stats
$4.74
-$0.22(-4.44%)
At close: 4:00 PM EDT
$4.74
-$0.22(-4.44%)
Day’s Range― - ―
52-Week Range$2.33 - $8.51
Previous Close$4.73
Volume74.35K
Average Volume (3M)42.75K
Market Cap
$150.15M
Enterprise Value$87.36
Total Cash (Recent Filing)$28.20M
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 10, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding32,290,170
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside121.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$2.15M
Bulls Say, Bears Say
Bulls Say
FDA Submission & EngagementAn active FDA submission with productive agency engagement materially reduces regulatory uncertainty versus peer early-stage diagnostics. Continued interaction and the expectation of first U.S. orders this year create a durable de-risking pathway for commercial launch and payer conversations over the next 2–6 months.
Medicare Reimbursement AnchorA concrete Medicare reimbursement rate establishes a sustainable revenue-per-test anchor that supports pricing, provider adoption economics, and sales planning. This reimbursement clarity materially strengthens commercial prospects and long-term revenue visibility versus tests without an established U.S. payer benchmark.
Platform, ISO & Registry MomentumISO 13485 certification, rising registry participation and an organ-agnostic assay expand commercial scalability and clinical credibility. Combined with management's $2B TAM view, these structural assets support multi-organ expansion and faster clinical adoption that can sustain growth once regulatory and placement hurdles ease.
Bears Say
Falling Revenue & Negative Gross ProfitA >50% TTM revenue decline and a negative gross profit indicate the core commercial model has not reached sustainable unit economics. Without meaningful volume growth or margin recovery, the business will struggle to absorb fixed costs, making profitability and internal funding unlikely over the coming quarters.
Very High Cash BurnPersistent multi‑million negative operating and free cash flow and a Q2 burn spike >$9M create structural runway pressure. Ongoing external financings or cost reductions will be required to sustain R&D and commercialization, raising dilution and execution risk across the next several quarters.
Negative Equity & Balance-sheet RiskNegative shareholders' equity reflects accumulated losses and reduces financial flexibility, increasing dependence on external capital or equity compensation. This structural weakness elevates refinancing and dilution risk and constrains options for M&A, partnerships, or margin‑preserving financing over the medium term.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $2.33 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $150.15M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Aug 10, 2026 which is in 2 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.142.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,290,170 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went up 25.882%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (121.52% Upside)
$10.50 (121.52% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.02%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
null
IMDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear operational and regulatory progress (FDA submission engagement, ISO certification, registry momentum, pricing validation, TAM affirmation, emerging head-to-head data and organ expansion), balanced against near-term financial pressures (Q2 cash burn >$9M, very low near-term revenue ~$0.25M), commercialization constraints (instrument placement), and timing uncertainty in Europe and FDA review details. Management provided concrete targets for margins, cost structure, and runway management and expects cash burn to decline in the back half of the year. Overall, the call signals meaningful de-risking and commercialization preparation while acknowledging near-term financial drag.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$10.50
▲(121.52% Upside)
Technical Analysis
Ownership Overview
79.85% Insiders
2.28% Mutual Funds
1.75% Other Institutional Investors
13.74% Public Companies and
Individual Investors